Ropinirole (SK and F 101468) Participating in the study were seven patients with presumed Parkinson's disease (mean age 56 5 years, disease duration 2 5 years and mean Hoehn and Yahr Stage II) and seven patients with disabling levodopainduced on-off oscillations (median age 66 years, disease duration 10 0 years and duration of levodopa treatment 4 0 years, daily levodopa dose 750 mg, median duration of disabling oscillations 1 0 years, mean Hoehn and Yahr stage when "off" III and when "on" II). Four of the patients treated with levodopa had severe interdose chorea and one patient had biphasic dyskinesias. Three patients were also receiving anticholinergic medication, three were taking L-deprenyl (selegiline); none of the patients had a history of psychiatric disorder or evidence ofhepatic, renal or cardiovascular dysfunction.
Both groups were initially treated with 0-6 mg of ropinirole twice daily for one week. The dose was increased to 1 mg twice daily for the second week and by further weekly increments of 1 mg twice daily to a maximum of 7 mg twice a day over an eight week period. If adverse reactions developed, patients continued on the previously tolerated dose for another week or a dose increase of less than 1 mg twice a day was made; if gastrointestinal side-effects or symptomatic orthostatic hypotension re-occurred, despite modification of ropinirole dosing, domperidone 20 mg twice daily was given, in some cases, for the remaining trial period. If interdose dyskinesias increased in the oscillating patients levodopa was concomitantly reduced. After each dose increment observations oflying and standing pulse and blood pressure were made at baseline and then hourly for the following four hours.
Motor assessments were carried out on the day of dose increase before and two hours after dosing, using the Modified Webster scale2 and tapping and walking tests.3 Assessments of motor fluctuations were carried out using self-scoring diaries to record a percentage daily "on" time and severity of dyskinesias.
Of the previously untreated patients two showed improvement comparable with that seen with oral levodopa at doses of 12 mg and 6 mg a day respectively. We conclude that ropinirole has anti-Parkinsonian effect and that the optimum dose range for most patients may be 4-8 mg a day.
Adverse reactions are similar to those seen with other dopamine receptor agonists and can be reduced by the use of domperidone and possibly more gradual dose increments than occurred in this trial. We would recommend in future that oral levodopa and subcutaneous apomorphine tests are carried out on previously untreated patients with Parkinson's syndrome4 before the assessment of a new dopaminergic agonist, to exclude as far as possible patients with multi-system degeneration unresponsive to this group of drugs. In the assessment of autonomic neuropathy, two widely used tests of cardiovascular autonomic function assess the heart rate response to three consecutive Valsalva manoeuvres and to six consecutive deep breaths.' We aimed to see whether the response to a single Valsalva manoeuvre was significantly different from that from the average of three and whether the response to a single deep breath was significantly different from that from the average of six deep breaths.
The study group consisted of 36 diabetic patients, 25 male and 11 female, 15 insulin treated, mean age 54 years (range 30-82), mean duration of diabetes 17-4 years (range 3 months-51 years). All had symptoms which may have been due to diabetic neuropathy.
They underwent heart rate monitoring using a computer-assisted system for the collection and analysis of heart rate data for cardiovascular autonomic function tests (RR Medical Electronics, Leeds, UK). A Valsalva manoeuvre was performed by the patient blowing into the tube of a sphygmomanometer and sustaining a pressure of 40 mm Hg for 15 seconds while the R-R interval was recorded, the result being expressed as the Valsalva ratio: the longest R-R interval during the 45 seconds after the manoeuvre divided by the shortest R-R interval during the manoeuvre. All the patients performed the manoeuvre properly and, as far as could be ascertained, achieved an intrathoracic pressure which was adequately raised. Heart rate variability during deep breathing was calculated by the patient resting quietly and breathing deeply in for over five seconds and
